Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.78 USD | -0.62% | +9.38% | +93.52% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 337M |
---|---|---|---|---|---|
Net income 2024 * | -160M | Net income 2025 * | -183M | EV / Sales 2024 * | - |
Net cash position 2024 * | 224M | Net cash position 2025 * | 396M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.97
x | P/E ratio 2025 * |
-1.82
x | Employees | 74 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.82% |
Latest transcript on Ventyx Biosciences, Inc.
1 day | -0.62% | ||
1 week | +9.38% | ||
1 month | +2.14% | ||
3 months | -43.76% | ||
6 months | +117.27% | ||
Current year | +93.52% |
Managers | Title | Age | Since |
---|---|---|---|
Raju Mohan
FOU | Founder | 67 | 18-10-31 |
Martin Auster
DFI | Director of Finance/CFO | 49 | 21-04-30 |
John Nuss
CTO | Chief Tech/Sci/R&D Officer | 65 | 18-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Somu Subramaniam
BRD | Director/Board Member | 69 | 18-10-31 |
Allison Hulme
BRD | Director/Board Member | 61 | 23-01-10 |
Sheila Gujrathi
CHM | Chairman | 53 | 21-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.17% | 2 M€ | -.--% | ||
0.09% | 0 M€ | 0.00% | - | |
0.05% | 7 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 4.78 | -0.62% | 425,542 |
24-05-30 | 4.81 | -2.43% | 429,231 |
24-05-29 | 4.93 | -3.90% | 559,669 |
24-05-28 | 5.13 | +17.39% | 1,504,571 |
24-05-24 | 4.37 | -1.80% | 341,647 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+93.52% | 337M | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- VTYX Stock